EGLN3/PHD3 Antibody (EG188e/d5) - BSA Free

HIF prolyl 4-hydroxylases (PHDs) are proyl hydroxylase domain-containing enzymes (PHD1/ Egln2, PHD2/ Egln1, PHD3/ Egln3, and P4H-TM) which are known for their role in mediating physiological responses to hypoxic stress via modulation of HIF1alpha expression levels. HIF-alpha subunit is regulated by hydroxylation, both by a family of PHDs leading to ubiquitination and proteasomal degradation, and by transcriptional inactivation following asparaginyl hydroxylation by FIH (factor inhibiting HIF). When oxygen levels are normal, HIF Prolyl Hydroxylase 3 (HIF-PH3/ PHD3/ Egln3) hydroxylates a specific proline found in HIF1A'a NODD/CODD domains and also hydroxylates HIF2A with preference for CODD site for HIF1A/HIF2A. Once hydroxylated, HIFs undergo proteasomal degradation via von Hippel-Lindau (VHL) ubiquitination complex. Upon hypoxic trigger, the hydroxylation reaction is tempered which let HIFs to escape degradation process leading to their nuclear translocation, heterodimerization with HIF1B, and increased expression of hypoxy-inducible genes. HIF-PH3 is the most important isozyme in limiting physiological activation of HIFs (particularly HIF2A) in hypoxia. Besides HIFs, in hypoxic conditions HIF-PH3 also hydroxylates PKM (thereby limiting glycolysis) and hydroxylates/regulates the stability of ADRB2. In cardiomyocytes, HIF-PH3 inhibits Bcl2's anti-apoptotic effect by disrupting the BAX-BCL2 complex, and in neurons, HIF-PH3 has a NGF-induced proapoptotic effect mediated via CASP3 activity regulation. HIF-PH3 also plays a crucial role in DNA damage response by hydroxylating TELO2, promoting its interaction with ATR which is required for activation of the ATR/CHK1/p53 pathway.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 3 confirmed species: Human, Rat, Sheep.

We have publications tested in 3 applications: IF/IHC, IHC-P, WB.

Showing Publications 1 - 10 of 10.

Publications using NBP1-30440	Applications	Species
Lock MC, Botting KJ, Allison BJ et al. MitoQ as an antenatal antioxidant treatment improves markers of lung maturation in healthy and hypoxic pregnancy The Journal of physiology 2023-07-19 [PMID: 37467062] (WB, Sheep)	WB	Sheep
Pavlakis D, Kampantais S, Gkagkalidis K et al. Hypoxia-Inducible Factor 2a Expression Is Positively Correlated With Gleason Score in Prostate Cancer Technology in cancer research & treatment 2021-03-23 [PMID: 33752529] (IHC-P, Human)	IHC-P	Human
Capitanio D, Moriggi M et al. Comparative proteomic analyses of Duchenne muscular dystrophy and Becker muscular dystrophy muscles: changes contributing to preserve muscle function in Becker muscular dystrophy patients. J Cachexia Sarcopenia Muscle 2020-01-04 [PMID: 31991054] (WB, Human)	WB	Human
Bur H, Haapasaari K M et al. Strong Prolyl Hydroxylase Domain 1 Expression Predicts Poor Outcome in Radiotherapy-treated Patients with Classical Hodgkin's Lymphoma. Anticancer Res 2018-01-01 [PMID: 29277791] (IF/IHC, Human)	IF/IHC	Human
Zhang G H, Yu F C et al. Prolyl 4-Hydroxylase Domain Protein 3 Overexpression Improved Obstructive Sleep Apnea-Induced Cardiac Perivascular Fibrosis Partially by Suppressing Endothelial-to-Mesenchymal Transition. J Am Heart Assoc 2017-10-19 [PMID: 29051216] (WB, Human)	WB	Human
Mysore VS, Szablowski J, Dervan PB, Frost PJ. A DNA-binding Molecule Targeting the Adaptive Hypoxic Response in Multiple Myeloma Has Potent Antitumor Activity. Mol Cancer Res. [PMID: 26801054] (WB, Human)	WB	Human
Fujita N, Gogate SS, Chiba K et al. Prolyl Hydroxylase 3 (PHD3) Modulates Catabolic Effects of Tumor Necrosis Factor-alpha (TNF-alpha) on Cells of the Nucleus Pulposus through Co-activation of Nuclear Factor kappaB (NF-kappaB)/p65 Signaling J Biol Chem 2012-11-16 [PMID: 22948157] (WB, Rat)	WB	Rat
Soilleux EJ, Turley H, Tian YM et al. Use of novel monoclonal antibodies to determine the expression and distribution of the hypoxia regulatory factors PHD-1, PHD-2, PHD-3 and FIH in normal and neoplastic human tissues. Histopathology. 2005-12-01 [PMID: 16324198] (IHC-P, Human)	IHC-P	Human
Stolze IP, Tian YM, Appelhoff RJ et al. Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (FIH) in regulating hypoxia-inducible factor (HIF) transcriptional target genes [corrected]. J Biol Chem. 2004-10-01 [PMID: 15302861]
Appelhoff RJ et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Bil Chem 279: 38458-38465. 2004-01-01 [PMID: 15247232] (WB, Human)	WB	Human

Images	Ratings	Applications	Species	Date	Details
Enlarge	5 reviewed by: Verified Customer	WB	Human	04/16/2019	View Summary Application Western Blot Sample Tested HBE-16 Species Human Lot B-1
Enlarge	4 reviewed by: Verified Customer	WB	Human	11/20/2015	View Summary Application Western Blot Sample Tested MCF-7 whole cell lysate Species Human Lot B-1
	5 reviewed by: Verified Customer	WB	Other	10/30/2014	View Summary Application Western Blot Sample Tested SK-N-BE(2) whole cell lysate Species Other Lot A
	5 reviewed by: Verified Customer	WB	Other	08/27/2014	View Summary Application Western Blot Sample Tested PC12 whole cell lysate Species Other Lot A

Array NBP1-30440

• EGLN3/PHD3 Antibodies
• EGLN3/PHD3 Lysate
• EGLN3/PHD3 Proteins